BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32638093)

  • 1. Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer.
    Shimizu T; Nishio K; Sakai K; Okamoto I; Okamoto K; Takeda M; Morishita M; Nakagawa K
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):211-219. PubMed ID: 32638093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.
    Dai CH; Shu Y; Chen P; Wu JN; Zhu LH; Yuan RX; Long WG; Zhu YM; Li J
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3786-3798. PubMed ID: 30315932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
    Saito H; Fukuhara T; Furuya N; Watanabe K; Sugawara S; Iwasawa S; Tsunezuka Y; Yamaguchi O; Okada M; Yoshimori K; Nakachi I; Gemma A; Azuma K; Kurimoto F; Tsubata Y; Fujita Y; Nagashima H; Asai G; Watanabe S; Miyazaki M; Hagiwara K; Nukiwa T; Morita S; Kobayashi K; Maemondo M
    Lancet Oncol; 2019 May; 20(5):625-635. PubMed ID: 30975627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer.
    Giaccone G; Zatloukal P; Roubec J; Floor K; Musil J; Kuta M; van Klaveren RJ; Chaudhary S; Gunther A; Shamsili S
    J Clin Oncol; 2009 Sep; 27(27):4481-6. PubMed ID: 19687333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.
    Okamoto K; Okamoto I; Hatashita E; Kuwata K; Yamaguchi H; Kita A; Yamanaka K; Ono M; Nakagawa K
    Mol Cancer Ther; 2012 Jan; 11(1):204-13. PubMed ID: 22075159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
    Tolcher AW; Mita A; Lewis LD; Garrett CR; Till E; Daud AI; Patnaik A; Papadopoulos K; Takimoto C; Bartels P; Keating A; Antonia S
    J Clin Oncol; 2008 Nov; 26(32):5198-203. PubMed ID: 18824702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.
    Shimizu T; Yonesaka K; Hayashi H; Iwasa T; Haratani K; Yamada H; Ohwada S; Kamiyama E; Nakagawa K
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):489-495. PubMed ID: 28144730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors.
    Satoh T; Okamoto I; Miyazaki M; Morinaga R; Tsuya A; Hasegawa Y; Terashima M; Ueda S; Fukuoka M; Ariyoshi Y; Saito T; Masuda N; Watanabe H; Taguchi T; Kakihara T; Aoyama Y; Hashimoto Y; Nakagawa K
    Clin Cancer Res; 2009 Jun; 15(11):3872-80. PubMed ID: 19470738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.
    Padda SK; Reckamp KL; Koczywas M; Neal JW; Kawashima J; Kong S; Huang DB; Kowalski M; Wakelee HA
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):105-115. PubMed ID: 34773474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
    Nakahara T; Yamanaka K; Hatakeyama S; Kita A; Takeuchi M; Kinoyama I; Matsuhisa A; Nakano K; Shishido T; Koutoku H; Sasamata M
    Anticancer Drugs; 2011 Jun; 22(5):454-62. PubMed ID: 21389848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
    Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
    Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913.
    Nakahara Y; Shimokawa T; Misumi Y; Nogami N; Shinkai T; Seki N; Hosomi Y; Hida N; Okamoto H
    Invest New Drugs; 2021 Feb; 39(1):202-209. PubMed ID: 32803700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
    Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
    Reck M; Garon EB; Paz-Ares L; Ponce S; Jaime JC; Juan O; Nadal E; Kiura K; Widau RC; He S; Dalal R; Lee P; Nakagawa K
    Clin Lung Cancer; 2018 May; 19(3):213-220.e4. PubMed ID: 29317191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
    Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
    Kelly RJ; Thomas A; Rajan A; Chun G; Lopez-Chavez A; Szabo E; Spencer S; Carter CA; Guha U; Khozin S; Poondru S; Van Sant C; Keating A; Steinberg SM; Figg W; Giaccone G
    Ann Oncol; 2013 Oct; 24(10):2601-2606. PubMed ID: 23857959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
    Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T
    Lung Cancer; 2015 Jun; 88(3):275-81. PubMed ID: 25891541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
    Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
    Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.